1597403-95-6Relevant academic research and scientific papers
Access to pyridines via cascade nucleophilic addition reaction of 1,2,3-triazines with activated ketones or acetonitriles
Zhang, Yuan,Luo, Han,Lu, Qixing,An, Qiaoyu,Li, You,Li, Shanshan,Tang, Zongyuan,Li, Baosheng
, p. 393 - 396 (2020/05/18)
We studied the cascade nucleophilic addition reactions of 1,2,3-triazines with activated acetonitriles or ketones, which were used to construct highly substituted pyridines that are not easily accessed by conventional methods. The strategy addressed some structural diversity issues currently facing medicinal chemistry, and the resulting pyridines could be used as convenient precursors for the synthesis of related pharmaceuticals. In particular, our method was applied to the syntheses of the marketed drug etoricoxib and several biologically important molecules in a few steps.
Synthetic method and applications of polysubstituted pyridine derivative
-
Paragraph 0107; 0110-0111, (2020/04/22)
The invention belongs to the field of organic chemical synthesis, and relates to a synthetic method and applications of a polysubstituted pyridine derivative. According to the method, a 2,3-triazine compound and a ketone compound are used as reaction substrates, and can be subjected to a one-step reaction under the action of a catalytic amount of an alkali to synthesize polysubstituted pyridine, wherein the reaction does not involve in the use of danger and controlled drugs, so that a simple, safe, efficient and environment-friendly way is provided for synthesis of polysubstituted pyridine. According to the invention, the reaction can also be used for synthesis of drug molecules, such as one-step synthesis of drug molecule etoricoxib and a derivative thereof; and the product obtained by the invention is further derivatized to obtain multiple types of pyridine functional group-containing active molecules, such as two-step synthesis of active molecules 2-SORA.
Discovery of 5″-chloro-n-[(5,6-dimethoxypyridin-2- yl)methyl]-2,2':5',3″-Terpyridine-3'-carboxamide (mk-1064): A selective orexin 2 receptor antagonist (2-sora) for the treatment of insomnia
Roecker, Anthony J.,Mercer, Swati P.,Schreier, John D.,Cox, Christopher D.,Fraley, Mark E.,Steen, Justin T.,Lemaire, Wei,Bruno, Joseph G.,Harrell, C. Meacham,Garson, Susan L.,Gotter, Anthony L.,Fox, Steven V.,Stevens, Joanne,Tannenbaum, Pamela L.,Prueksaritanont, Thomayant,Cabalu, Tamara D.,Cui, Donghui,Stellabott, Joyce,Hartman, George D.,Young, Steven D.,Winrow, Christopher J.,Renger, John J.,Coleman, Paul J.
, p. 311 - 322 (2014/04/03)
The field of small-molecule orexin antagonist research has evolved rapidly in the last 15 years from the discovery of the orexin peptides to clinical proof-of-concept for the treatment of insomnia. Clinical programs have focused on the development of antagonists that reversibly block the action of endogenous peptides at both the orexin 1 and orexin 2 receptors (OX1R and OX2R), termed dual orexin receptor antagonists (DORAs), affording late-stage development candidates including Merck's suvorexant (new drug application filed 2012). Full characterization of the pharmacology associated with antagonism of either OX1R or OX2R alone has been hampered by the dearth of suitable subtype-selective, orally bioavailable ligands. Herein, we report the development of a selective orexin 2 antagonist (2-SORA) series to afford a potent, orally bioavailable 2-SORA ligand. Several challenging medicinal chemistry issues were identified and overcome during the development of these 2,5-disubstituted nicotinamides, including reversible CYP inhibition, physiochemical properties, P-glycoprotein efflux and bioactivation. This article highlights structural modifications the team utilized to drive compound design, as well as in vivo characterization of our 2-SORA clinical candidate, 5''-chloro-N- [(5,6-dimethoxypyridin-2-yl)methyl] -2,2':5',3''-terpyridine-3'-carboxamide (MK-1064), in mouse, rat, dog, and rhesus sleep models.
